Targeting the Natriuretic Peptide System to Improve Outcomes: PARADISE Lost or Found.

Competing Interests: Funding Support and Author Disclosures Dr Udell has received speaker/consulting fees from Amgen, AstraZeneca, Boehringer Ingelheim, Canadian Cardiovascular Research Network, Canadian Cardiovascular Society, Eli Lilly, GlaxoSmithKline, Janssen, Merck, Novartis, Novavax, Novo Nordisk, Sanofi, University Health Network, and University of Toronto; and has received grant support to his institutions from Bayer, Boehringer Ingelheim, and Janssen. Dr Armstrong has reported that he has no relationships relevant to the contents of this paper to disclose.